Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Cantor Fitzgerald
Farmers Insurance
Teva
McKinsey
Julphar
Chubb
AstraZeneca

Generated: February 23, 2019

DrugPatentWatch Database Preview

Litigation Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2011)

« Back to Dashboard

Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2011)

Docket ➤ Sign Up Date Filed 2011-11-03
Court District Court, D. Delaware Date Terminated 2014-09-17
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Parties ACTAVIS INC.; ACTAVIS SOUTH ATLANTIC LLC; ACTAVIS, INC.; LTS LOHMANN THERAPIE-SYSTEME AG; NOVARTIS AG; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.; NOVARTIS PHARMA AG; NOVARTIS PHARMACEUTICALS CORPORATION; PAR PHARMACEUTICAL INC.; WATSON LABORATORIES INC.; WATSON PHARMA INC.; WATSON PHARMACEUTICALS INC.
Patents 4,948,807; 5,602,176; 6,316,023; 6,335,031; 6,699,498
Attorneys Andrea M. Houston; C. Nicole Gifford; Daniel G. Brown; Daniel M. Silver; Dominick T. Gattuso; Erika R. Caesar; Erin A. Thomson; Gina R. Gencarelli; James L. Higgins; Jennifer Koh; Melanie K. Sharp; Michael P. Kelly; Michelle R. Ma; Robert M. Vrana; Stephen M. Hash
Firms Ballard Spahr LLP; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc.
The small molecule drugs covered by the patents cited in this case are ➤ Sign Up and ➤ Sign Up .

Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2011)

Date Filed Document No. Description Snippet Link To Document
2011-11-03 1 United States Letters Patent No. 5,602,176 (“the ’176 patent”). The ’176 patent was duly and legally …United States Letters Patent No. 6,316,023 (“the ’023 patent”). The ’023 patent was duly and legally issued…United States Letters Patent No. 6,335,031 (“the ’031 patent”). The ’031 patent was duly and legally issued…the ’031 patent is attached hereto as Exhibit C. 26. The ’023 and ’031 patents were initially…the ’176, ’023, and ’031 patents was an act of infringement of these patents. External link to document
2011-12-01 13 admits the face of United States Patent No. 5,602,176 (the “’176 patent”) states that it was issued on …P-laintift`s’ purported claims for patent infringement arise under the patent laWs, but denies that such claims… Plaintiffs’ claims for patent infringement purport to arise under the patent laws of the United States…true copy of the ’ 176 patent Actavis believes that the claims of the ’ 176 patent speak for themselves …admits the face of United States Patent No. 6,316,023 (the “’023 patent”) states that it was issued on External link to document
2011-11-03 3 09/21/2011. Date of Expiration of Patent: 02/11/2014 for 5,602,176, 01/08/2019 for 6,316,023 B1 and 6,335,031… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) … 17 September 2014 1:11-cv-01077-RGA Patent None District Court, D. Delaware External link to document
2013-09-27 311 (R)-enantiomer, is U.S. patent 4,948,807 (the “’807 patent”). The ’807 patent, which is also listed in…States patents 6,335,031 (“’031 patent”) and 6,316,023 (“’023 patent”)(collectively the “patents-in-suit…Claims of the Patents-In-Suit The ‘031 and ‘023 patents are related patents The patents share common …Another earlier patent, also owned by Plaintiffs, U.S. patent 5 ,602,176 (the “’ 176 patent”), claims and…the ’572 patent and the Handbook. 2. Claim 7 of the ’023 Patent and Claim 7 of the ’031 Patent Would Have External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Cipla
AstraZeneca
Accenture
US Army
Federal Trade Commission
QuintilesIMS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.